trial

Efficacy and Safety of Celecoxib as Add-on Therapy to Risperidone Versus Risperidone Alone in Patients With Schizophrenia

NCTId NCT00639483
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 270 (actual)
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
270 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2003-03
Primary completion
—
Eligibility
ALL · 18 Years · 50 Years

Interventions & indications

Drugs
celecoxib

Sponsors

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Lead Sponsor

Sites

17 total
La Plata, ArgentinaLanus, ArgentinaLa Plata, ArgentinaPR, BrazilSalvador, BrazilAparecida de Goiânia, BrazilRio de Janeiro, BrazilSão Paulo, BrazilBonn, GermanyMünchen, GermanyMünchen, GermanyMünster, Germany

Facts & assertions

3 sourced
Enrollment
270
Phase
PHASE2
Status
COMPLETED
relationships
The graph out of here
drug
celecoxib
drug
lead_sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
company
indication
Schizophrenia
indication
Schizophrenia
indication